News

There appears to be no link between a unique pattern of the gut microbiome — the genetic material carried by all of the microorganisms, such as bacteria, living in the gut — and mild cognitive impairment in people with Parkinson’s disease, a study found. The study, “Gut microbiome…

Scientists exploring the potential of machine learning approaches in drug discovery for Parkinson’s disease and other neurodegenerative disorders — focusing on misfolded proteins that are the hallmark of such conditions — found that one such method identified compounds “two orders of magnitude more potent” than ones previously reported, per…

People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers at the University of Florida found. The mutation, called RAB32 Ser71Arg, was identified in 16 individual families from different ethnic groups and increased the activation of the LRRK2 protein, a…

The Parkinson’s Foundation has joined forces with Tasso — a U.S. company that offers a sample collection and logistics platform for clinical trials — to accelerate genetic research into the underpinnings of Parkinson’s disease. The collaboration will harness Tasso’s patient-friendly blood collection technology to acquire small blood…

Six months of daily tavapadon, as an oral add-on therapy to standard levodopa, significantly increased on time without troublesome dyskinesia, or involuntary body movements, in people in the late stages of Parkinson’s disease, according to top-line data from a Phase 3 study. Data from the trial, dubbed…

A three-week ketogenic diet, one low in carbohydrates and high in fat, supplemented with a specific type of fat — called medium chain triglycerides — showed no significant benefits in easing motor symptoms in a small group of people with Parkinson’s disease, a pilot trial has found. Whether this…

People with Parkinson’s disease who experience digestive issues or probable rapid eye movement (REM) sleep behavior disorder may be as much as twice as likely to develop symptoms of psychosis, a study found. Understanding what predicts early-onset psychosis in Parkinson’s can help doctors identify at-risk patients sooner, enabling them…

A Phase 1/2 clinical trial dubbed ASPIRO that’s testing Aspen Neuroscience’s ANPD001 — a stem cell therapy candidate designed to replace the nerve cells that are lost in Parkinson’s disease — has dosed its first patient. A first transplant was conducted at the Banner-University Medical Center Tucson by…

Sage Therapeutics’ dalzanemdor, formerly known as SAGE-718, an investigational oral medication for mild cognitive impairment (MCI) due to Parkinson’s disease, has failed to outperform a placebo in a Phase 2 study. Based on these top-line data from the trial, called PRECEDENT (NCT05318937), Sage will stop any further…

Updated exercise guidelines for those with Parkinson’s disease released by The Michael J. Fox Foundation (MJFF) now include Nordic pole walking as a suggested aerobic activity to help mitigate symptoms and improve everyday life. The exercise, a Finnish-derived low-impact total body walk, is also known as urban…